1. Search Result
Search Result
Results for "

SARS

" in MedChemExpress (MCE) Product Catalog:

766

Inhibitors & Agonists

3

Screening Libraries

3

Fluorescent Dye

2

Biochemical Assay Reagents

48

Peptides

46

Inhibitory Antibodies

80

Natural
Products

210

Recombinant Proteins

52

Isotope-Labeled Compounds

6

Click Chemistry

6

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9803

    SARS-80R; SARS Antibody-80R

    SARS-CoV Infection
    Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
    Anti-SARS-80R mAb
  • HY-P9807

    SARS-CR3022; SARS-CoV-2 Antibody-CR3022

    SARS-CoV Infection Inflammation/Immunology
    Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
    Anti-SARS-CoV-2 Spike mAb (CR3022)
  • HY-151608

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-3 is a potent M pro inhibitor with an IC50 value of ﹥5 μM. SARS-CoV-2 Mpro-IN-3 can be used in research of COVID-19 .
    SARS-CoV-2 Mpro-IN-3
  • HY-149955

    SARS-CoV Infection
    SARS-CoV-2-IN-38 (compound 24) is a SARS-CoV-2 inhibitor with good oral bioavailability in mice (F%=39.75%) .
    SARS-CoV-2-IN-38
  • HY-150691

    SARS-CoV Cancer
    SARS 3CLpro-IN-1 (Compound 3b) is a SARS 3CL protease inhibitor with an IC50 value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole .
    SARS 3CLpro-IN-1
  • HY-155308

    SARS-CoV Infection
    SARS-CoV-2-IN-61 (compound 8i) is a SARS CoV-2 PLpro inhibitor with an IC50 of 16 µM. SARS-CoV-2-IN-61 has antiviral activities .
    SARS-CoV-2-IN-61
  • HY-162924

    SARS-CoV Infection
    SARS-CoV-IN-6 (Compound 17) is an inhibitor of SARS-CoV-1 and SARS-CoV-2 RdRp, with an IC50 value of 7.8 μM against SARS-CoV-2 RdRp. SARS-CoV-IN-6 reduces cytopathic effects in cells infected with SARS-CoV-1 and SARS-CoV-2 replicon-based single-round infectious particles (SRIPs), and inhibits SARS-CoV N protein expression, with EC50 values of 0.12 µM for SARS-CoV-1 replicon-based SRIPs and 1.47 µM for SARS-CoV-2 replicon-based SRIPs .
    SARS-CoV-IN-6
  • HY-150783

    SARS-CoV Infection
    SARS-CoV-2-IN-24 (compound 7) is a potent papain-like protease (PL pro) inhibitor. SARS-CoV-2-IN-24 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. SARS-CoV-2-IN-24 can be used for SARS-CoV-2 research .
    SARS-CoV-2-IN-24
  • HY-143467

    SARS-CoV Infection
    SARS-CoV-IN-4 (compound 13) is a potent and specific inhibitor of SARS-CoV nsp14 N7-methyltransferase, with an IC50 of 0.6 μM (SARS-CoV nsp14) .
    SARS-CoV-IN-4
  • HY-155119

    SARS-CoV Infection
    SARS-CoV-2-IN-54 (Compound 2) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-54 has antiviral activity. SARS-CoV-2-IN-54 inhibits SARS-CoV-2 in Vero E6 cells, with an IC50 of 21.4 μM .
    SARS-CoV-2-IN-54
  • HY-155121

    SARS-CoV Infection
    SARS-CoV-2-IN-56 (Compound 63) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-56 has antiviral activity. SARS-CoV-2-IN-56 inhibits SARS-CoV-2 in Vero E6 cells, with an IC50 of 0.7 μM .
    SARS-CoV-2-IN-56
  • HY-149954

    SARS-CoV Infection
    SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 against SARS-CoV-2 by inhibiting of SKP2 protein and stabilizing BECN1 .
    SARS-CoV-2-IN-39
  • HY-163913

    SARS-CoV Infection
    SARS-CoV-IN-5 (compound 49) is a highly selective, nonpeptidic and noncovalent 3CL pro inhibitor with IC50s of 38 nM, 21.1 nM and 86 nM for 3CL pro of SARS-CoV-1, SARS-CoV-2, Bat coronavirus WIV1, respectively. SARS-CoV-IN-5 inhibits the replication of the SARS-CoV-2 delta variant with an EC50 of 0.272 μM. SARS-CoV-IN-5 significantly reduces the lung viral copies in a K18-hACE2 transgenic mouse model. SARS-CoV-IN-5 has good target-specific and potential broad-spectrum anticoronavirus activities against SARS-CoV-1, WIV1, MERS, HCoV-OC43, HCoV-229E, and HKU9 .
    SARS-CoV-IN-5
  • HY-136606

    SARS-CoV Infection
    SARS-CoV MPro-IN-1 is a SARS-CoV-2 3CLpro covalent inhibitor, with an IC50 of 40 nM. SARS-CoV MPro-IN-1 shows good anti-SARS-CoV-2-infection activity in cell culture with an EC50 of 0.33 μM. SARS-CoV MPro-IN-1 has the potential for COVID-19 research .
    SARS-CoV MPro-IN-1
  • HY-162790

    SARS-CoV Virus Protease Infection
    SARS-CoV-2-IN-95 (Compound 10) is an inhibitor for SARS-CoV-2 PLpro with an IC50 of 0.39 μM. SARS-CoV-2-IN-95 exhibits antiviral activity in mouse SARS-CoV-2-infected model .
    SARS-CoV-2-IN-95
  • HY-156008

    SARS-CoV Virus Protease Infection
    SARS-CoV-2-IN-58 (Compound 21H) is an antiviral agent against SARS-CoV-2 (EC50: 18 μM). SARS-CoV-2-IN-58 inhibits SARS-CoV-2 M pro with an IC50 of 0.35 μM .
    SARS-CoV-2-IN-58
  • HY-163713

    SARS-CoV Infection
    SARS-CoV-2-IN-89 (Compound 2) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-89 enhances IFN-I responses to SARS-CoV-2 infection in A549.hACE2 cells .
    SARS-CoV-2-IN-89
  • HY-151988

    SARS-CoV Infection
    SARS-CoV-2-IN-36 is a potent SARS-CoV-2 Mpro (SARS-CoV) inhibitor with an IC50 of 2.37 μM and a Kd of 1.19 μM in enzymatic assays. SARS-CoV-2-IN-36 shows antiviral activity against UC-1074, RG2674, and NVDBB-2220 SARS-CoV-2 variants in Vero cells .
    SARS-CoV-2-IN-36
  • HY-155015

    SARS-CoV Infection
    SARS-CoV-2-IN-45 (Compound 8p) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-45 inhibits SARS-CoV-2 replication in Calu-3 cell with an EC50 of 0.5 μM, and has no evident cytotoxic effect .
    SARS-CoV-2-IN-45
  • HY-162154

    SARS-CoV Infection
    SARS-CoV-2-IN-75 (compound 13) is a SARS-CoV-2 inhibitor based on chloroacetamide inhibition. SARS-CoV-2-IN-75 inhibits cellular SARS-CoV-2 replication with an EC68 (half-log reduction in viral titer) of 3 μM .
    SARS-CoV-2-IN-75
  • HY-163857

    SARS-CoV Infection
    SARS-CoV-2-IN-91 (Compound 194) is an inhibitor for SARS-CoV 2 with an EC50 of 28.92 μM. SARS-CoV-2-IN-91 inhibits the viral -1 programmed ribosome frame shift (-1PRF) element, and thereby inhibits the replication of SARS-CoV 2 .
    SARS-CoV-2-IN-91
  • HY-135860

    Virus Protease SARS-CoV Infection
    SARS-CoV-2-IN-1 is a potent Mpro inhibitor. SARS-CoV-2-IN-1 inhibits the purified recombinant SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with IC50s of 0.67, 0.90 and 0.58 μM, respectively .
    SARS-CoV-2-IN-1
  • HY-159477

    SARS-CoV Infection Inflammation/Immunology
    SARS-CoV-2-IN-92 (compound 11) inhibits SARS-CoV-2 variants (EC50 = 0.48 μM), as well as SARS-CoV and MERS-CoV. SARS-CoV-2-IN-92 (compound 11) potently and selectively blocks ERα-Glu II .
    SARS-CoV-2-IN-92
  • HY-162604

    SARS-CoV Infection
    SARS-CoV-2-IN-90 (compound 3i) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-90 can be used in coronavirus infection related research .
    SARS-CoV-2-IN-90
  • HY-135858
    SARS-CoV-IN-3
    1 Publications Verification

    SARS-CoV Parasite HIV Infection
    SARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-3 shows anti-Coronavirus activity with an EC50 of 3.6 μM in Vero cells. SARS-CoV-IN-3 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 11.7 and 20.4 nM; and IC90s of 29.19 and 56 nM; respectively. SARS-CoV-IN-3 reduces HIV-1-induced cytopathic effect with an EC50 of 10 μM in MT-4 cells .
    SARS-CoV-IN-3
  • HY-162177

    SARS-CoV Infection
    SARS-CoV-2-IN-78 (compound 3) is an inhibitor for nsp14 of SARS-Cov-2. SARS-CoV-2-IN-78 reveals antiviral activity as N7 methyltrabsferase .
    SARS-CoV-2-IN-78
  • HY-162777

    SARS-CoV Infection
    SARS-CoV-2-IN-93 (compound 24) is an inhibitor of SARS-CoV-2 and HCoV-OC43. SARS-CoV-2-IN-93 can be used in antiviral research .
    SARS-CoV-2-IN-93
  • HY-149304

    SARS-CoV Infection
    SARS-CoV-2-IN-40 (Compound 19) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC50s of 100 nM and 160 nM respectively .
    SARS-CoV-2-IN-40
  • HY-169224

    SARS-CoV Infection
    SARS-CoV-2-IN-100 (Compound 172) is an inhibitor of SARS-CoV-2, demonstrating broad-spectrum antiviral activity against various SARS-CoV-2 variants. SARS-CoV-2-IN-100 exhibits synergistic effects with Nirmatrelvir, which can reduce the risk of antiviral drug resistance .
    SARS-CoV-2-IN-100
  • HY-146379

    SARS-CoV Infection
    SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of SARS-CoV-2 with an EC50 of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases .
    SARS-CoV-2-IN-19
  • HY-143417

    SARS-CoV Infection
    SARS-CoV-2-IN-16 (Compound 12) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-16 exhibits potent anti-viral activity with the EC50 of 3.69 μM. SARS-CoV-2-IN-16 binds to NPro with the low KD value of 7.82 μM, suggesting that SARS-CoV-2-IN-16 is a potent NPro ligand .
    SARS-CoV-2-IN-16
  • HY-143418

    SARS-CoV Infection
    SARS-CoV-2-IN-17 (Compound 16) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-17 exhibits potent anti-viral activity with the EC50 of 2.18 μM. SARS-CoV-2-IN-17 binds to NPro with the low KD value of 7.82 μM, suggesting that SARS-CoV-2-IN-17 is a potent NPro ligand .
    SARS-CoV-2-IN-17
  • HY-135855
    SARS-CoV-IN-1
    1 Publications Verification

    SARS-CoV Parasite Infection
    SARS-CoV-IN-1 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-1 shows anti-Coronavirus activity with an EC50 of 4.9 μM in Vero cells. SARS-CoV-IN-1 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 15.4 and 133.2 nM; and IC90s of 25.7 and 459.1 nM; respectively. Antimalarial and antiviral activities .
    SARS-CoV-IN-1
  • HY-157022

    SARS-CoV Infection
    SARS-CoV-2-IN-67 (Compound 16), a vitamin K derivatives, has anti-SARS-CoV-2 activity (EC50: 64.8 μM in VeroE6/TMPRSS2 cells). SARS-CoV-2-IN-67 inhibits SARS-CoV-2 RdRp activity .
    SARS-CoV-2-IN-67
  • HY-157145

    SARS-CoV Infection
    SARS-CoV-2-IN-69 (Compound 7E) is a non-covalent SARS-CoV-2 inhibitor with an EC50 value of 7.4 μM. SARS-CoV-2-IN-69 is a potent inhibitor of SARS-CoV-2 main protease (M pro) and a non-covalent inhibitor of papain (PL pro) .
    SARS-CoV-2-IN-69
  • HY-163067

    SARS-CoV Infection
    SARS-CoV-2-IN-71 (compound 8h) is a potent inhibitor of SARS-CoV-2. SARS-CoV-2-IN-71 inhibits coronavirus replication at multiple stages. SARS-CoV-2-IN-71 displays anti-coronaviral effect by simultaneously acting on 3CL pro and TMPRSS2 .
    SARS-CoV-2-IN-71
  • HY-135856
    SARS-CoV-IN-2
    1 Publications Verification

    SARS-CoV Parasite HIV Infection
    SARS-CoV-IN-2 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-2 shows anti-Coronavirus activity with an EC50 of 1.9 μM in Vero cells. SARS-CoV-IN-2 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 21.5 and 30 nM; and IC90s of 51.0 and 99.9 nM; respectively. SARS-CoV-IN-2 reduces HIV-1-induced cytopathic effect with an EC50 of 2.9 μM in MT-4 cells. Antimalarial and Antiviral Activities .
    SARS-CoV-IN-2
  • HY-146381

    SARS-CoV Infection
    SARS-CoV-2-IN-20 (Compound 1a) is a potent inhibitor of SARS-CoV-2 with an EC50 of 6.5 μM. SARS-CoV-2-IN-20 has the potential for the research of infection diseases .
    SARS-CoV-2-IN-20
  • HY-158687

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-18 (compound 84) is a potent SARS-CoV-2 Mpro inhibitor with the IC50 of 3.23 nM. SARS-CoV-2 Mpro-IN-18 can be used for study of anti-SARS-CoV-2 agent .
    SARS-CoV-2 Mpro-IN-18
  • HY-145276

    SARS-CoV Infection
    SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
    SARS-CoV-2-IN-10
  • HY-145277

    SARS-CoV Infection
    SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
    SARS-CoV-2-IN-11
  • HY-154975

    SARS-CoV Others
    SARS-CoV-2-IN-49 is an irreversible covalent inhibitor of SARS-CoV-2 main protease .
    SARS-CoV-2-IN-49
  • HY-162984

    SARS-CoV Cancer
    SARS-CoV-2-IN-99 (compund 58) is a SARS-CoV-2 main protease inhibitor .
    SARS-CoV-2-IN-99
  • HY-149315

    SARS-CoV Infection
    SARS-CoV-2-IN-48 (compound 19) is a SARS-CoV-2 inhibitor with an IC50 of 2.7 μM for Omicron BA.1. SARS-CoV-2-IN-48 shows antiviral activities .
    SARS-CoV-2-IN-48
  • HY-P3492

    SARS-CoV Infection
    SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .
    SARS-CoV-2-IN-34
  • HY-148387

    SARS-CoV Infection
    SARS-CoV-2-IN-35 is a potent and orally active SARS-CoV-2 M pro inhibitor with a Ki value of 12.1 nM. SARS-CoV-2-IN-35 can be used in research of COVID-19 .
    SARS-CoV-2-IN-35
  • HY-149868

    SARS-CoV Infection
    SARS-CoV-2-IN-42 (Compound 8q) is a potent inhibitor of SARS-CoV-2 replication (EC50: 0.4 μM). SARS-CoV-2-IN-42 has no obvious damage to the host cell .
    SARS-CoV-2-IN-42
  • HY-157144

    SARS-CoV Infection
    SARS-CoV-2-IN-68 (compound 6C) is a covalent SARS-CoV-2 PLpro/Mpro inhibitor with potent antiviral activities. SARS-CoV-2-IN-68 binds to Zn-finger domain of PLpro .
    SARS-CoV-2-IN-68
  • HY-168600

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-32 (Compound 1) is a selective inhibitor of SARS-CoV-2 M Pro with an IC50 value of 230 nM. SARS-CoV-2 Mpro-IN-32 can also inhibit the replication of multiple SARS-CoV-2 variants in vitro .
    SARS-CoV-2 Mpro-IN-32
  • HY-151267

    SARS-CoV Infection
    SARS-CoV-2-IN-25 (Compound CP026) is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC50 of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes .
    SARS-CoV-2-IN-25

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: